ASH 2023 | Preliminary results of a Phase II study of fedratinib in patients with MDS/MPN and CNL
Andrew Kuykendall, MD, Moffitt Cancer Center, Tampa, FL, discusses the preliminary findings of a Phase II trial (NCT05177211) investigating the use fedratinib in patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes and chronic neutrophilic leukemia (CNL). This patient group is often underrepresented in trials as this spectrum of diseases is challenging to treat, leading to a lack of focused treatment recommendations. Dr Kuykendall comments on the highly encouraging preliminary efficacy data of the ongoing trial, and eagerly anticipates the translational correlative data, which will provide an understanding of how the drug is impacting underlying disease processes. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Celgene/BMS, Cogent, Incyte, Abbvie, Imago, Novartis, PharmaEssentia, CTI Biopharma, MorphoSys, GSK, Karyopharm
Research Funding: MorphoSys, BMS, Protagonist Therapeutics, Janssen
Advisory Board: Dark Blue Therapeutics
